No long-term benefit of low-dose OKT3 induction therapy in non to moderately immunized renal allograft recipients.
Bemelman
F J
FJ
Department of Nephrology, Academic Medical Centre, Amsterdam, The Netherlands.
Yong
S
S
Parlevliet
K J
KJ
Surachno
S
S
Schellekens
P T A
PT
ten Berge
R J M
RJ
D000328:Adult; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006085:Graft Survival / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007518:Isoantibodies / Q000097:blood; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D018579:Patient Selection; D011241:Prednisone / Q000627:therapeutic use; D016019:Survival Analysis; D013997:Time Factors; D014184:Transplantation, Homologous / Q000276:immunology
D007166:Immunosuppressive Agents; D007518:Isoantibodies; D016853:Muromonab-CD3; D016572:Cyclosporine; D011241:Prednisone